{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Enzalutamide Plus ADT",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Enzalutamide 160 mg (four 40 mg capsules) once daily plus androgen deprivation therapy (LHRH agonist/antagonist or bilateral orchiectomy)."
      },
      {
        "id": "arm_2",
        "name": "Placebo Plus ADT",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Placebo capsules identical in appearance to enzalutamide once daily plus androgen deprivation therapy (LHRH agonist/antagonist or bilateral orchiectomy)."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "High volume of disease",
        "instanceType": "StudyCohort",
        "characteristic": "Metastases involving viscera or 4+ bone lesions (1+ beyond vertebral column/pelvis)"
      },
      {
        "id": "cohort_2",
        "name": "Low volume of disease",
        "instanceType": "StudyCohort",
        "characteristic": "Metastatic disease not meeting high volume criteria"
      },
      {
        "id": "cohort_3",
        "name": "Prior docetaxel",
        "instanceType": "StudyCohort",
        "characteristic": "Subjects who received 1-6 cycles of docetaxel therapy"
      },
      {
        "id": "cohort_4",
        "name": "No prior docetaxel",
        "instanceType": "StudyCohort",
        "characteristic": "Subjects who have not received prior docetaxel therapy"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Enzalutamide Plus ADT - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Enzalutamide Plus ADT during Screening"
      },
      {
        "id": "elem_2",
        "name": "Enzalutamide Plus ADT - Double-blind Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Enzalutamide Plus ADT during Double-blind Treatment Period"
      },
      {
        "id": "elem_3",
        "name": "Enzalutamide Plus ADT - Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Enzalutamide Plus ADT during Safety Follow-up"
      },
      {
        "id": "elem_4",
        "name": "Enzalutamide Plus ADT - Long-term Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Enzalutamide Plus ADT during Long-term Follow-up"
      },
      {
        "id": "elem_5",
        "name": "Enzalutamide Plus ADT - Open-Label Extension",
        "instanceType": "StudyElement",
        "description": "Treatment period for Enzalutamide Plus ADT during Open-Label Extension"
      },
      {
        "id": "elem_6",
        "name": "Placebo Plus ADT - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo Plus ADT during Screening"
      },
      {
        "id": "elem_7",
        "name": "Placebo Plus ADT - Double-blind Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo Plus ADT during Double-blind Treatment Period"
      },
      {
        "id": "elem_8",
        "name": "Placebo Plus ADT - Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo Plus ADT during Safety Follow-up"
      },
      {
        "id": "elem_9",
        "name": "Placebo Plus ADT - Long-term Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo Plus ADT during Long-term Follow-up"
      },
      {
        "id": "elem_10",
        "name": "Placebo Plus ADT - Open-Label Extension",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo Plus ADT during Open-Label Extension"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 10,
      "cohortCount": 4,
      "elementCount": 10
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator",
        "Outcome Assessor"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Volume of disease (low versus high)",
        "Prior docetaxel therapy (no prior docetaxel, 1-5 cycles, 6 cycles)"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2",
        "cohort_3",
        "cohort_4"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Urology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator",
          "Outcome Assessor"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Volume of disease (low versus high)",
          "Prior docetaxel therapy (no prior docetaxel, 1-5 cycles, 6 cycles)"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Oncology",
        "Urology"
      ]
    },
    "arms": [
      {
        "name": "Enzalutamide Plus ADT",
        "type": "Experimental Arm",
        "description": "Enzalutamide 160 mg (four 40 mg capsules) once daily plus androgen deprivation therapy (LHRH agonist/antagonist or bilateral orchiectomy).",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Placebo Plus ADT",
        "type": "Placebo Comparator",
        "description": "Placebo capsules identical in appearance to enzalutamide once daily plus androgen deprivation therapy (LHRH agonist/antagonist or bilateral orchiectomy).",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "High volume of disease",
        "characteristic": "Metastases involving viscera or 4+ bone lesions (1+ beyond vertebral column/pelvis)"
      },
      {
        "name": "Low volume of disease",
        "characteristic": "Metastatic disease not meeting high volume criteria"
      },
      {
        "name": "Prior docetaxel",
        "characteristic": "Subjects who received 1-6 cycles of docetaxel therapy"
      },
      {
        "name": "No prior docetaxel",
        "characteristic": "Subjects who have not received prior docetaxel therapy"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Weeks -4 to -1 (28 days)"
      },
      {
        "name": "Double-blind Treatment Period",
        "description": "Day 1 until documented radiographic progression, initiation of new therapy, or intolerable toxicity"
      },
      {
        "name": "Safety Follow-up",
        "description": "30 days after last dose of study drug"
      },
      {
        "name": "Long-term Follow-up",
        "description": "Every 12 weeks until death, final OS analysis, or study termination"
      },
      {
        "name": "Open-Label Extension",
        "description": "Optional period for subjects continuing to receive clinical benefit after OS analysis or study termination"
      }
    ]
  }
}